Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J advises following labels

This article was originally published in The Tan Sheet

Executive Summary

Following the death of a Staten Island, N.Y. teenager caused by overuse of Bengay and other OTC anti-inflammatory muscle creams and other products, Johnson & Johnson advised consumers to follow label instructions on all OTCs. In a statement, J&J says Bengay "should be applied to the affected area not more than 3-4 times daily and consumers should stop use and see a doctor if the condition worsens or if symptoms persist for more than seven days." On June 9, the New York City Medical Examiner's Office stated 17-year old Arielle Newman died April 3 from an accidental overdose of methyl salicylate, the active ingredient in Bengay and other sports balms. An office spokesperson says continuous overuse created a toxic level of methyl salicylate in the girl's system. In addition to using the creams between track meets, the girl was using adhesive pads with methyl salicylate and an unknown third product containing the anti-inflammatory ingredient, the spokesperson says, adding it is the office's first reported death caused by sports cream...

You may also be interested in...

Neuroscience Challenges Oncology For Top Spot In CDER’s 2019 Novel Approvals

Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.

In Case You Missed It … News On China Patents, EMA Chief, And More

We clean out your Martin Luther King Day inbox so you don't have to.

At Muted J.P. Morgan, Focus Is Execution, But US Pricing Is Persistent Overhang

Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts